aldoxorubicin
Small moleculeexperimental
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6-maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker. — Wikipedia
Clinical trial activity
27 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
22
Phase 3
3
Phase 4
0
Earliest trial started May 1, 2008 (NCT00472771)
Timeline
Indications
Studied for
- Acquired Immunodeficiency Syndrome · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Chordoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Down Syndrome · Phase 3
- Glioblastoma · Phase 2
- Hamartoma · Phase 3
- HIV Infections · Phase 2
- Hodgkin Disease · Phase 3
- Leiomyosarcoma · Phase 3
- Leukemia · Phase 3
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Liposarcoma · Phase 3
- Lymphoma · Phase 2/Phase 3
- Lymphoma, AIDS-Related · Phase 1
- Lymphoma, B-Cell · Phase 2/Phase 3
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 3
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoma, T-Cell · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Plasmablastic Lymphoma · Early Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Sarcoma · Phase 2
- Sarcoma, Kaposi · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Testicular Neoplasms · Phase 3
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- DNA topoisomerase II alphaINHIBITOR
TOP2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl- Mol. weight
- 787.22 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2107827 ↗
- WikipediaAldoxorubicin ↗
- ChEMBLCHEMBL2107818 ↗
Also known as
- aldoxo
- aldoxorubicin
- aldoxorubicin
- aldoxorubicin
- aldoxorubicin
- doxo-emch
- inno-206
- inno-206
- inno-206
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04390399 | Phase 2 | May 11, 2020 | ImmunityBio, Inc. |
| NCT04031677 | Phase 3 | Apr 21, 2020 | European Organisation for Research and Treatment of Cancer, Netherlands Cancer Institute, University of Milan |
| NCT03574649 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03554109 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03563144 | Phase 2 | Aug 31, 2018 | NantWorks |
| NCT03647423 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | NantWorks |
| NCT03586869 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2018 | NantWorks |
| NCT03563170 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03563157 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03387085 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | NantWorks |
| NCT03822936 | Phase 2 | Feb 8, 2018 | CNAO National Center of Oncological Hadrontherapy, Foundation IRCCS San Matteo Hospital |
| NCT03387111 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2018 | NantWorks |
| NCT03387098 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2018 | NantWorks |
| NCT03213977 | Phase 3 | Feb 1, 2017 | Fujian Medical University |
| NCT02570412 | N/A | Oct 6, 2015 | CytRx |
| NCT02200757 | Phase 2 | Sep 1, 2014 | CytRx |
| NCT02235688 | Phase 1 | Aug 1, 2014 | CytRx |
| NCT02235701 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2014 | CytRx |
| NCT02014844 | Phase 2 | Mar 1, 2014 | CytRx |
| NCT02049905 | Phase 3 | Jan 1, 2014 | CytRx |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytRx | For profit | 13 | 13 | 4 | 2008 |
| NantWorks | For profit | 10 | 10 | 1 | 2018 |
| CNAO National Center of Oncological Hadrontherapy | Academic/Hospital | 1 | 1 | 1 | 2018 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Foundation IRCCS San Matteo Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| ImmunityBio, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2020 |
10 organizations
Page 1 / 1